Moderna's early data shows its COVID-19 vaccine is 94.5% effective
American biotechnology company Moderna on Monday announced its experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage clinical trial. Moderna's interim analysis was based on 95 infections among trial participants who received either a placebo or the vaccine. Among those, only five infections occurred in those who received the vaccine.